COMPUGEN news, videos and press releases
For more news please use our advanced search feature.
COMPUGEN - More news...
COMPUGEN - More news...
- /C O R R E C T I O N -- Compugen Ltd./
- Compugen Reports Fourth Quarter and Full Year 2024 Results
- Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
- Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
- Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
- Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
- Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
- Compugen Reports Third Quarter 2024 Results
- Compugen to Participate in Stifel 2024 Healthcare Conference
- Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
- Compugen Strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions
- Compugen Strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions
- Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
- Compugen to Present New Clinical Data at SITC 2024
- Compugen to Present at Single Cell Genomics 2024 Conference
- Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Compugen Reports Second Quarter 2024 Results
- Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
- Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
- Compugen to Present at Upcoming Antibody Industrial Symposium
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
- Compugen Reports First Quarter 2024 Results
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
- Compugen to Participate in Two Upcoming Investor Conferences
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
